Why is Summit Therapeutics stock plunging today?
Summit Therapeutics (SMMT) stock fell 17.5% to $11.68 after the FDA issued a Complete Response Letter for its lung cancer treatment, citing insufficient overall survival data. Analysts had mixed reactions, with Jefferies seeing limited downside and Barclays lowering its price target to $18. The company remains committed to the drug's development. The Nasdaq was down 0.9%, adding to market pressure.
How this was made
The 30-second read
Why it matters
The regulatory denial removes the primary catalyst for near‑term revenue, prompting a sell‑side reaction and heightened volatility.
Market read
The news directly drives a 17.5% drop in Summit's stock, with potential spill‑over to other biotech names awaiting FDA decisions.
What to watch
Potential partnership or licensing deals for ivonescimab could mitigate the impact of the CRL.
Background
Summit Therapeutics announced a Complete Response Letter from the FDA for its ivonescimab BLA, leading to a sharp pre‑market sell‑off.
Ticker impact
FDA issued a Complete Response Letter rejecting Summit Therapeutics' BLA for ivonescimab, causing a 17.5% pre‑market drop.
likely continued decline as investors reassess the regulatory pathway.
The CRL is a material regulatory setback for a biotech with a flagship asset; the stock already fell 17.5% pre‑open.
Market effects
Biotech sector may see broader risk aversion after a high‑profile FDA denial.
US Nasdaq likely pressured by the drop in a biotech name.
Limited to investors tracking FDA outcomes; no immediate global macro effect.
Counterpoint
If Summit can secure additional data to address overall survival, the stock may rebound on a later positive readout.
Key entities
- companySummit Therapeutics
Biopharma developing ivonescimab for NSCLC.
- regulatorFDA
U.S. Food and Drug Administration issuing the CRL.




